— Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected. — Total revenues grew by 23% to $2.05 billion versus $1.99 billion expected. Eylea sales increased by 16% to $1.19 billion. — Dupixent sales, which soared by 141% to $633 million, drove higher profitability … Continue reading Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot